NCT06108596View on ClinicalTrials.gov

Evaluation of the Efficacy and Safety of Interleucin-2 Combined With PD-1 Monoclonal Antibody and CAPOX in Preoperative Neoadjuvant Therapy for Mid-low Locally Advanced Rectal Cancer - a Single-center, Single-arm, Open-label Clinical Trail

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

October 21, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Locally Advanced Rectal Adenocarcinoma
Interventions
DRUG

Sintilimab with Interleukin-2+CAPOX

Sintilimab with Interleukin-2+CAPOX

Trial Locations (1)

210000

Jiangsu Province Hospital, Nanjing

All Listed Sponsors
lead

The First Affiliated Hospital with Nanjing Medical University

OTHER

NCT06108596 - Evaluation of the Efficacy and Safety of Interleucin-2 Combined With PD-1 Monoclonal Antibody and CAPOX in Preoperative Neoadjuvant Therapy for Mid-low Locally Advanced Rectal Cancer - a Single-center, Single-arm, Open-label Clinical Trail | Biotech Hunter | Biotech Hunter